 | |
| Clinical data | |
|---|---|
| Other names | 3,4-Methylenedioxy-α-ethyl-N-methylbenzylamine; α-Ethyl-N-methylpiperonylamine; 1-Methylamino-1-(3,4-methylenedioxyphenyl)propane |
| Routes of administration | Oral[1] |
| Drug class | Unknown[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ~6 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO2 |
| Molar mass | 193.246 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
M-ALPHA, also known as3,4-methylenedioxy-α-ethyl-N-methylbenzylamine or asα-ethyl-N-methylpiperonylamine, is apsychoactive drug of thesubstituted benzylamine group.[1][2] It was reported byAlexander Shulgin in his bookPIHKAL as apositional isomer ofMDMA.[1][2] Subsequently, the drug was encountered as adesigner drug in theUnited Kingdom in 2010 and was reported to theEMCDDA new drug monitoring service.[3] It was described by Shulgin as similar in action to itsdemethylatedhomologue,ALPHA, but with roughly twice theduration and twice thepotency.[1] ALPHA itself was described as active at doses of 10 to 140 mg, with a duration of about 3 hours, and producing eyes-closed "dreams", some body tingling, and a pleasant positive feeling, but without anyappetite suppression.[1] M-ALPHA was encountered as a designer drug by 2010.[4]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |
